المؤلفون: Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, François-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques-Olivier, Gutierrez, Francisco Llamas, Menard, Cédric, Tarte, Karin, Delfau, Marie-Hélène, Portugues, Cédric, Itti, Emmanuel, Palard-Novello, Xavier, Blanc-Durand, Paul, Al Tabaa, Yassine, Bailly, Clément, Laurent, Camille, Lemonnier, François

المساهمون: Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang Rennes (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Service Hématologie - IUCT-Oncopole CHU Toulouse, Pôle Biologie CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hématologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'Hémato-oncologie CHU Saint-Louis, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Amiens-Picardie, Cancer and Brain Genomics (CBG), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Lipides - Nutrition - Cancer Dijon - U1231 (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, CHU Henri Mondor Créteil, The Lymphoma Academic Research Organisation Lyon (LYSARC), CRLCC Eugène Marquis (CRLCC), UNICANCER, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de médecine nucléaire Montpellier, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers (CRCI2NA ), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Kite, a Gilead company

المصدر: ISSN: 1078-8956.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: International audience ; Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, roughly half of patients with R/R LBCL are deemed unsuitable candidates for ASCT. The efficacy of axi-cel remains to be ascertained in transplant-ineligible patients. ALYCANTE, an open-label, phase 2 study, evaluated axi-cel as a second-line therapy in 62 patients with R/R LBCL who were considered ineligible for ASCT. The primary end point was investigator-assessed complete metabolic response at 3 months from the axi-cel infusion. Key secondary end points included progression-free survival, overall survival and safety. The study met its primary end point with a complete metabolic response of 71.0% (95% confidence interval, 58.1-81.8%) at 3 months. With a median follow-up of 12.0 months (range, 2.1-17.9), median progression-free survival was 11.8 months (95% confidence interval, 8.4-not reached) and overall survival was not reached. There was no unexpected toxicity. Grade 3-4 cytokine release syndrome and neurologic events occurred in 8.1% and 14.5% of patients, respectively. These results support axi-cel as second-line therapy in patients with R/R LBCL ineligible for ASCT. ClinicalTrials.gov Identifier: NCT04531046 .

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37710005; hal-04212634; https://hal.science/hal-04212634Test; https://hal.science/hal-04212634/documentTest; https://hal.science/hal-04212634/file/s41591-023-02572-5.pdfTest; PUBMED: 37710005; PUBMEDCENTRAL: PMC10579056

الإتاحة: https://doi.org/10.1038/s41591-023-02572-5Test
https://hal.science/hal-04212634Test
https://hal.science/hal-04212634/documentTest
https://hal.science/hal-04212634/file/s41591-023-02572-5.pdfTest

المؤلفون: Beauvais, David, Robin, Christine, Thiebaut, Anne, Alain, Sophie, Coiteux, Valerie, Ducastelle-Lepretre, Sophie, Marcais, Ambroise, Ceballos, Patrice, Xhaard, Alienor, Redjoul, Rabah, Nguyen, Stephanie, Brissot, Eolia, Joris, Magalie, Turlure, Pascal, Rubio, Marie-Therese, Chevallier, Patrice, Benard, Nathalie, Liautard, Camille, Yakoub-Agha, Ibrahim

المساهمون: CHU Lille, Inserm, Université de Lille, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Hôpital Henri Mondor, Université Paris-Est Créteil Val-de-Marne - Paris 12 UPEC UP12, CHU Grenoble, CHU Limoges, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques RESINFIT, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Hôpital Necker - Enfants Malades AP-HP, Hôpital Saint Eloi CHRU Montpellier, Hopital Saint-Louis AP-HP AP-HP, CHU Pitié-Salpêtrière AP-HP, Centre de Recherche Saint-Antoine UMRS893, CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Nancy CHRU Nancy, Centre hospitalier universitaire de Nantes CHU Nantes

مصطلحات موضوعية: CMV infection, Letermovir, Primary prophylaxis, Allogeneic hematopoietic cell transplantation, Cytomegalovirus

الوصف: We report the results of the French Temporary Authorization of Use (ATU) compassionate program of letermovir for primary prophylaxis conducted in 21 transplant centers. Patients were CMV seropositive allogeneic hematopoietic cell transplantation recipients and at high risk for CMV infection. Primary prophylaxis was defined as initiation of letermovir between day 0 and day +28 post-transplant. Between November 2017 and January 2019, 96 patients with a median age of 56 years received letermovir and follow-up data were available for 78 patients. The median time from transplant to letermovir initiation was 4 days, and the median duration of exposure to letermovir was 78 days, with 57 patients still on treatment at the cutoff date. Letermovir was temporarily discontinued in 4 patients (5.1%) and stopped in 39 patients (50.0%), in most cases due to planned end of treatment (n = 16, 20.5%). Fifteen patients (19.2%) each presented one positive CMV PCR, in median 13 days after letermovir initiation. Clinically significant CMV infection was reported in 5 patients (6.4%). No CMV disease was reported. At least one adverse drug reaction was reported for 12 patients (15.4%). In this early access program, letermovir was effective with comparable results of the phase 3 study with a low rate of clinically significant CMV infection, including in patients who were at high-risk for CMV infection. ; 148

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8

العلاقة: Journal of clinical virology . the official publication of the Pan American Society for Clinical Virology; J Clin Virol; http://hdl.handle.net/20.500.12210/75274Test

الإتاحة: https://doi.org/20.500.12210/75274Test
https://hdl.handle.net/20.500.12210/75274Test

المؤلفون: Lebon Delphine, Debureaux Pierre-Edouard, Royer Bruno, Gruson Bérengère, Joris Magalie, Votte Patrick, Marolleau Jean-Pierre, Morel Pierre

المصدر: Medical Sciences; Volume 11; Issue 1; Pages: 14

مصطلحات موضوعية: autologous hematopoietic stem cell transplantation, central nervous system lymphoma, infections, conditioning, adverse events

الوصف: In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen. However, 11 percent of the patients died due to toxicity. Besides conventional survival, progression-free survival and treatment related mortality analyses, a competing-risk analysis was applied to our cohort of twenty-four consecutive patients with primary or secondary central nervous system lymphoma who underwent autologous stem cell transplantation after thiotepa busulfan cyclophosphamide conditioning. The two-year overall survival and progression-free survival rates were 78 percent and 65 percent, respectively. The treatment-related mortality rate was 21 percent. The competing risks analysis demonstrate that age 60 or over and the infusion of less than 4.6 × 106/kg CD34+ stem cells were significant adverse prognostic factors for overall survival. Autologous stem cell transplantation with thiotepa busulfan cyclophosphamide conditioning was associated with sustained remission and survival. Nevertheless, the intensive thiotepa busulfan cyclophosphamide conditioning regimen was highly toxic, especially in older patients. Thus, our results suggest that future studies should aim at identifying the subgroup of patients who will really benefit of the procedure and/or to reduce the toxicity of future conditioning regimen.

وصف الملف: application/pdf

العلاقة: https://dx.doi.org/10.3390/medsci11010014Test

الإتاحة: https://doi.org/10.3390/medsci11010014Test

المؤلفون: Chantepie, Sylvain, Huguet, Françoise, Hunault, Mathilde, Roth Guepin, Gabrielle, Balsat, Marie, Pilar Gallego Hernanz, Maria, Joris, Magalie, Karangwa, Alexandre, Ojeda Uribe, Mario, Santagostino, Alberto, Maury, Sébastien

المصدر: HemaSphere ; volume 7, issue S3, page e299054e ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000968516.29905.4eTest

المؤلفون: Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, Francois-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Rene Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques Olivier, Llamas, Francisco, Menard, Cedric, Tarte, Karin, Delfau-Larue, Marie-Helene, Itti, Emmanuel, Bailly, Clément, Al Tabaa, Yassine, Laurent, Camille, Lemonnier, Francois

المصدر: HemaSphere ; volume 7, issue S3, page e56791ba ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000967844.56791.baTest

المؤلفون: Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, François-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques-Olivier, Gutierrez, Francisco Llamas, Menard, Cédric, Tarte, Karin, Delfau, Marie-Hélène, Portugues, Cédric, Itti, Emmanuel, Palard-Novello, Xavier, Blanc-Durand, Paul, Al Tabaa, Yassine, Bailly, Clément, Laurent, Camille, Lemonnier, François

المصدر: Nature Medicine ; volume 29, issue 10, page 2665-2665 ; ISSN 1078-8956 1546-170X

مصطلحات موضوعية: General Biochemistry, Genetics and Molecular Biology, General Medicine

الإتاحة: https://doi.org/10.1038/s41591-023-02624-wTest
https://www.nature.com/articles/s41591-023-02624-w.pdfTest
https://www.nature.com/articles/s41591-023-02624-wTest

المؤلفون: Lebon, Delphine, Dujardin, Adèle, Caulier, Alexis, Joris, Magalie, Charbonnier, Amandine, Gruson, Bérengère, Quint, Marine, Castelain, Sandrine, François, Catherine, Lacassagne, Marie-Noëlle, Guillaume, Nicolas, Marolleau, Jean-Pierre, Morel, Pierre

المصدر: Leukemia Research ; volume 125, page 107005 ; ISSN 0145-2126

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.leukres.2022.107005Test
https://api.elsevier.com/content/article/PII:S0145212622003812?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0145212622003812?httpAccept=text/plainTest

المؤلفون: Durand, Gatien, Desoutter, Judith, Lorriaux, Corinne, Poumaredes, Géraldine, Joris, Magalie, Charbonnier, Amandine, Lebon, Delphine, Paubelle, Etienne, Garcon, Loïc, Guillaume, Nicolas

المساهمون: CHU Amiens-Picardie, Laboratoire d'Hématologie CHU Amiens, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 2059-2302 ; EISSN: 2059-2310.

مصطلحات موضوعية: [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology

الوصف: International audience ; In patients awaiting an allogeneic haematopoietic stem cell transplantation, platelet transfusion is a risk factor for anti‐HLA class I immunization because the resulting donor‐specific antibodies complicate the allograft process. The objective of the present study was to determine the feasibility of a novel eplet‐based strategy for identifying HLA class I mismatches between potential donors and the recipient when pre‐allograft platelet transfusions were required. We included 114 recipient/haploidentical relative pairs. For each pair, we entered HLA‐class I typing data into the HLA Eplet Mismatch calculator, defined the list of mismatched eplets (for the recipient versus donor direction) and thus identified the shared HLAs to be avoided. Using this list of HLAs, we defined the theoretical availability of platelet components (PCs) by calculating the virtual panel‐reactive antibody (vPRA). We also determined the number of PCs actually available in France by querying the regional transfusion centre's database. The mean ± standard deviation number of highly/moderately exposed eplets to be avoided in platelet transfusions was 5.8 ± 3.3, which led to the prohibition of 38.5 ± 2 HLAs‐A and ‐B. Taking into account the mismatched antigens and the eplet load, the mean ± standard deviation theoretical availability of PCs (according to the vPRA) was respectively 34.49% ± 1.95% for HLA‐A and 80% ± 2.3% for HLA‐B. A vPRA value below 94.9% for highly or moderately exposed eplets would predict that 10 PCs were actually available nationally. Although epitope protection of HLA molecules is feasible, it significantly restricts the choice of PCs.

العلاقة: hal-04520100; https://u-picardie.hal.science/hal-04520100Test

الإتاحة: https://doi.org/10.1111/tan.15438Test
https://u-picardie.hal.science/hal-04520100Test

المؤلفون: Lebon, Delphine, Dujardin, Adèle, Caulier, Alexis, Joris, Magalie, Charbonnier, Amandine, Gruson, Bérangère, Quint, Marine, Castelain, Sandrine, François, Catherine, Lacassagne, Marie-Noëlle, Guillaume, Nicolas, Marolleau, Jean-Pierre, Morel, Pierre

المساهمون: Université de Lille, CHU Lille, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 HEMATIM, CHU Amiens-Picardie, Université de Picardie Jules Verne UPJV, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

مصطلحات موضوعية: Graft versus host disease, Ruxolitinib, CMV reactivation, EBV reactivation

الوصف: Objectives Steroid-refractory graft-versus-host disease (SR-GVHD) is a challenging complication of allogeneic hematopoietic stem cell transplantation, and leads to high morbidity and mortality rates. The orally administered, selective Janus-associated kinase 1/2 inhibitor ruxolitinib gives overall response rates (ORR) of more than 70 % in acute and chronic SR-GVHD. However, several studies have highlighted an elevated risk of cytomegalovirus (CMV) reactivation in patients with ruxolitinib-treated SR-GVHD. Methods We therefore analyzed risk of CMV and Epstein-Barr virus (EBV) primary infection or reactivation in 57 patients with ruxolitinib-treated GVHD, while taking account of the competing risk (CR) of death prior to the first reactivation. Results Initiation of ruxolitinib treatment was a significant adverse prognostic factor for the CR of first CMV reactivation (hazard ratio (HR)= 1.747, 95 % confidence interval (CI): 1.33–2.92, p < 0.0001) and first EBV reactivation (HR=2.657, 95 % CI: 1.82–3.87, p < 0.0001) during GVHD. In our cohort of ruxolitinib-treated patients, the ORR (48 % and 58 % for acute and chronic GVHD, respectively) and the toxicity profile (haematological adverse events in 29.8 % of the patients) were similar to the literature values. Conclusion Given ruxolitinib’s efficacy in SR-GVHD, use of this drug should not be limited by the fear of viral reactivation; however, our present results emphasize the importance of monitoring the viral load. ; 125

العلاقة: Leukemia Research; Leuk Res; http://hdl.handle.net/20.500.12210/89889Test

الإتاحة: https://doi.org/20.500.12210/89889Test
https://hdl.handle.net/20.500.12210/89889Test

المؤلفون: Chalandon, Yves, Rousselot, Philippe, Chevret, Sylvie, Cayuela, Jean-Michel, Kim, Rathana, Huguet, Françoise, Chevallier, Patrice, Graux, Carlos, Thiebaut-Bertrand, Anne, Chantepie, Sylvain, Thomas, Xavier, Vincent, Laure, Berthon, Céline, Hicheri, Yosr, Raffoux, Emmanuel, Escoffre-Barbe, Martine, Plantier, Isabelle, Joris, Magalie, Turlure, Pascal, Pasquier, Florence, Belhabri, Amine, Guepin, Gabrielle Roth, Blum, Sabine, Gregor, Michael, Lafage-Pochitaloff, Marina, Quessada, Julie, Lhéritier, Véronique, Clappier, Emmanuelle, Boissel, Nicolas, Dombret, Hervé

المصدر: Blood; June 2024, Vol. 143 Issue: 23 p2363-2372, 10p

مستخلص: •Alternating reduced-intensity and conventional chemotherapy with nilotinib followed by SCT resulted in 4-year OS of 79.4% in Ph+ALL.•The omission of high-dose Ara-C during consolidation resulted in a significantly higher rate of relapses without affecting overall survival.